Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy by Yishen Tian, Jingxuan Li, Na Yang, Yang Zhao, Jiancao Zuo, Hang Xiong, Yiwen Pan, Li Xiao, Min Su, Feng Han, Zhixu He, Rong Hu

“…Experimental results demonstrated that this cellular preparation exhibited promising therapeutic effects in both melanoma and pancreatic cancer models. This research provided a novel platform for the synergistic cooperation of various methods in tumor immunotherapy, holding broad application prospects.…”
Get full text

Iodine activates NLRP3 inflammasomes in PBMCs of patients with autoimmune thyroiditis and regulates Th1 and Th17 cell differentiation by Ying Wu, Qingling Guo, Yongping Liu, Xun Gong, Wei Sun, Yushu Li, Chenling Fan, Weiping Teng, Zhongyan Shan

“…., NLRP1, NLRP3, absent in melanoma 2 (AIM2) and caspase-1), interleukin (IL)-1β and IL-18 were assessed using qRT-PCR and western blotting. …”
Get full text

Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy by James Dooley, Bart Neyns, Elizabeth Allen, Frank Tacke, Louis Boon, Damya Laoui, Julia Katharina Schwarze, Helena Van Damme, Bruno Dombrecht, Máté Kiss, Heleen Roose, Eva Van Overmeire, Daliya Kancheva, Liesbet Martens, Aleksandar Murgaski, Pauline Madeleine Rachel Bardet, Gillian Blancke, Maude Jans, Evangelia Bolli, Maria Solange Martins, Yvon Elkrim, Kiavash Movahedi, Niels Vandamme, Sebahat Ocak, Isabelle Scheyltjens, Lars Vereecke, Frank Aboubakar Nana, Pascal Merchiers, Jo Agnes Van Ginderachter

“…These findings were validated by flow cytometric analysis of both mouse (LLC-OVA, MC38 and B16-OVA) and human (NSCLC and melanoma) tumor samples. We generated two CCR8-specific nanobodies (Nbs) that recognize distinct epitopes on the CCR8 extracellular domain. …”
Get full text

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

“…We investigated the safety and tolerability of IMA202 in a first-in-human, dose escalation basket trial in human leucocyte antigen A*02:01 positive patients with melanoma-associated antigen A1 (MAGEA1)-positive advanced solid tumors.Trial design The 2+2 trial design was an algorithmic design based on a maximally acceptable dose-limiting toxicity (DLT) rate of 25% and the sample size was driven by the algorithmic design with a maximum of 16 patients. …”
Get full text

Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins by Maria Angelica Freitas-Cortez, Fatemeh Masrorpour, Hong Jiang, Iqbal Mahmud, Yue Lu, Ailing Huang, Lisa K. Duong, Qi Wang, Tiffany A. Voss, Claudia S. Kettlun Leyton, Bo Wei, Wai-Kin Chan, Kevin Lin, Jie Zhang, Efrosini Tsouko, Shonik Ganjoo, Hampartsoum B. Barsoumian, Thomas S. Riad, Yun Hu, Carola Leuschner, Nahum Puebla-Osorio, Jing Wang, Jian Hu, Michael A. Davies, Vinay K. Puduvalli, Cyrielle Billon, Thomas P. Burris, Philip L. Lorenzi, Boyi Gan, James W. Welsh

Get full text

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report by Yasar Subutay Peker, Mehmet Fatih Can, Ismail Hakki Ozerhan, Gokhan Yagci, Nazif Zeybek, Kutan Kavakli, Sedat Gurkok, Alper Gozubuyuk, Onur Genc, Gokhan Erdem, Ahmet Ozet, Mustafa Gerek, Yusuf Peker

“…BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. …”
Get full text

Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients by Christopher D. Roche, Joelle S. Dobson, Sion K. Williams, Mara Quante, Joyce Popoola, Jade W. M. Chow

“…Additionally, 21 patients (3.0%) only had noninvasive tumours. 221 malignant skin tumours were found: 50.2% were SCCs, 47.1% BCCs, and 2.7% malignant melanomas. Mean years to first tumour were 5.8. Mean number of tumours per patient was 4, with mean interval of 12 months. …”
Get full text

Topical Mitomycin C and Radiation Induce Conjunctival DNA-Polyploidy by Olaf Cartsburg, Christopher Kallen, Jost Hillenkamp, Rainer Sundmacher, Natalia Pomjanski, Alfred Böcking

“…Methods: Conjunctival brush smears were obtained from 13 patients (13 eyes) with squamous cell carcinomas and six patients (6 eyes) with conjunctival malignant melanomas in situ before, during and after treatment. …”
Get full text

Multi-stage structure-based virtual screening approach combining 3D pharmacophore, docking and molecular dynamic simulation towards the identification of potential selective PARP-1... by Mahmoud A. El Hassab, Wagdy M. Eldehna, Ghaneya S. Hassan, Sahar M. Abou-Seri

“…Elevated levels of PARP-1 were observed in many types of tumor cells, such as breast, lung, ovarian, prostate, and melanomas. In an attempt to provide a future guide for developing selective inhibitors for PARP-1 over PARP-2 to minimize the resulting side effects from PARP-2 inhibitors, we constructed a structure-based virtual screening approach (SBVS). …”
Get full text

Tp53 determines the spatial dynamics of M1/M2 tumor-associated macrophages and M1-driven tumoricidal effects by Yi-Jing Hsiao, Min-Shu Hsieh, Gee-Chen Chang, Yin-Chen Hsu, Chia-Yu Wang, Yan-Ming Chen, Yi-Ling Chen, Pan-Chyr Yang, Sung-Liang Yu

“…Furthermore, higher M1-signature was significantly associated with better responses and survival following anti-PD1 treatment in wtp53 melanomas. IFNs/STAT1/p53 signaling was critical for the anti-tumor activity of M1 macrophages. …”
Get full text